Pontin, a new mutant p53-binding protein, promotes gain-of-function of mutant p53

Cell Death and Differentiation

Volumn 22, Issue 11, 2015, Pages 1824-1836

  Zhao, Y ^a   Zhang, C ^a   Yue, X ^a   Li, X ^a   Liu, J ^a   Yu, H ^a   Belyi, V A ^a   Yang, Q ^a   Feng, Z ^a   Hu, W ^a  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; BINDING PROTEIN; PONTIN; PROTEIN P53; UNCLASSIFIED DRUG; CARRIER PROTEIN; DNA HELICASE; PROTEIN BINDING; RUVBL1 PROTEIN, HUMAN;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER PROGNOSIS; CELL INVASION; CELL MIGRATION; CELL VIABILITY; CHROMATIN ASSEMBLY AND DISASSEMBLY; COLORECTAL CANCER; CONTROLLED STUDY; EXPRESSION VECTOR; GAIN OF FUNCTION MUTATION; HCT116 CELL LINE; HUMAN; HUMAN CELL; LUNG CANCER; METASTASIS; MISSENSE MUTATION; MOUSE; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; THYMUS LYMPHOMA; TUMOR CELL; TUMOR GROWTH; UPREGULATION; ANIMAL; CARCINOGENESIS; CELL CYCLE; CELL MOTION; CELL SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; GENETICS; HCT 116 CELL LINE; IN VITRO STUDY; METABOLISM; MUTATION; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CARCINOGENESIS; CARRIER PROTEINS; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; DNA HELICASES; HCT116 CELLS; HUMANS; IN VITRO TECHNIQUES; MICE; MUTATION; PROTEIN BINDING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84943199938     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2015.33     Document Type: Article

References (45)

1. Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer 2009; 9: 749-758.
2. Muller PA, Vousden KH. p53 mutations in cancer. Nat Cell Biol 2013; 15: 2-8.
3. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004; 119: 861-872.
4. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004; 119: 847-860.
5. Zhang C, Liu J, Liang Y, Wu R, Zhao Y, Hong X et al. Tumour-associated mutant p53 drives the Warburg effect. Nat Commun 2013; 4: 2935.
6. Muller P, Hrstka R, Coomber D, Lane DP, Vojtesek B. Chaperone-dependent stabilization and degradation of p53 mutants. Oncogene 2008; 27: 3371-3383.
7. Zheng T, Wang J, Zhao Y, Zhang C, Lin M, Wang X et al. Spliced MDM2 isoforms promote mutant p53 accumulation and gain-of-function in tumorigenesis. Nat Commun 2013; 4: 2996.
8. Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes Dev 2012; 26: 1268-1286.
9. Gaiddon C, Lokshin M, Ahn J, Zhang T, Prives C. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol 2001; 21: 1874-1887.
10. Freed-Pastor WA, Mizuno H, Zhao X, Langerod A, Moon SH, Rodriguez-Barrueco R et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 2012; 148: 244-258.
11. Stambolsky P, Tabach Y, Fontemaggi G,Weisz L, Maor-Aloni R, Siegfried Z et al. Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell 2010; 17: 273-285.
12. Song H, Hollstein M, Xu Y. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol 2007; 9: 573-580.
13. Haupt S, di Agostino S, Mizrahi I, Alsheich-Bartok O, Voorhoeve M, Damalas A et al. Promyelocytic leukemia protein is required for gain of function by mutant p53. Cancer Res 2009; 69: 4818-4826.
14. Girardini JE, Napoli M, Piazza S, Rustighi A, Marotta C, Radaelli E et al. A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell 2011; 20: 79-91.
15. Jin J, Cai Y, Yao T, Gottschalk AJ, Florens L, Swanson SK et al. A mammalian chromatin remodeling complex with similarities to the yeast INO80 complex. J Biol Chem 2005; 280: 41207-41212.
16. Jha S, Shibata E, Dutta A. Human Rvb1/Tip49 is required for the histone acetyltransferase activity of Tip60/NuA4 and for the downregulation of phosphorylation on H2AX after DNA damage. Mol Cell Biol 2008; 28: 2690-2700.
17. Venteicher AS, Meng Z, Mason PJ, Veenstra TD, Artandi SE. Identification of ATPases pontin and reptin as telomerase components essential for holoenzyme assembly. Cell 2008; 132: 945-957.
18. Wood MA, McMahon SB, Cole MD. An ATPase/helicase complex is an essential cofactor for oncogenic transformation by c-Myc. Mol Cell 2000; 5: 321-330.
19. Feng Y, Lee N, Fearon ER. TIP49 regulates beta-catenin-mediated neoplastic transformation and T-cell factor target gene induction via effects on chromatin remodeling. Cancer Res 2003; 63: 8726-8734.
20. Lacombe J, Mange A, Jarlier M, Bascoul-Mollevi C, Rouanet P, Lamy PJ et al. Identification and validation of new autoantibodies for the diagnosis of DCIS and node negative earlystage breast cancers. Int J Cancer 2013; 132: 1105-1113.
21. Lauscher JC, Elezkurtaj S, Dullat S, Lipka S, Grone J, Buhr HJ et al. Increased Pontin expression is a potential predictor for outcome in sporadic colorectal carcinoma. Oncol Rep 2012; 28: 1619-1624.
22. Taniue K, Oda T, Hayashi T, Okuno M, Akiyama T. A member of the ETS family, EHF, and the ATPase RUVBL1 inhibit p53-mediated apoptosis. EMBO Rep 2011; 12: 682-689.
23. Tucker PA, Sallai L. The AAA+ superfamily-a myriad of motions. Curr Opin Struct Biol 2007; 17: 641-652.
24. Mezard C, Davies AA, Stasiak A, West SC. Biochemical properties of RuvBD113N: a mutation in helicase motif II of the RuvB hexamer affects DNA binding and ATPase activities. J Mol Biol 1997; 271: 704-717.
25. Elkaim J, Castroviejo M, Bennani D, Taouji S, Allain N, Laguerre M et al. First identification of small-molecule inhibitors of Pontin by combining virtual screening and enzymatic assay. Biochem J 2012; 443: 549-559.
26. Cronier L, Crespin S, Strale PO, Defamie N, Mesnil M. Gap junctions and cancer: new functions for an old story. Antioxid Redox Signal 2009; 11: 323-338.
27. Feng Z, Levine AJ. The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein. Trends Cell Biol 2010; 20: 427-434.
28. Tomas A, Futter CE, Eden ER. EGF receptor trafficking: consequences for signaling and cancer. Trends Cell Biol 2014; 24: 26-34.
29. Xia Y, Gong KZ, Xu M, Zhang YY, Guo JH, Song Y et al. Regulation of gap-junction protein connexin 43 by beta-adrenergic receptor stimulation in rat cardiomyocytes. Acta Pharmacologica Sinica 2009; 30: 928-934.
30. Guo K, Ma Q, Wang L, Hu H, Li J, Zhang D et al. Norepinephrine-induced invasion by pancreatic cancer cells is inhibited by propranolol. Oncol Rep 2009; 22: 825-830.
31. Bist P, Leow SC, Phua QH, Shu S, Zhuang Q, Loh WT et al. Annexin-1 interacts with NEMO and RIP1 to constitutively activate IKK complex and NF-kappaB: implication in breast cancer metastasis. Oncogene 2011; 30: 3174-3185.
32. Masciarelli S, Fontemaggi G, Di Agostino S, Donzelli S, Carcarino E, Strano S et al. Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells. Oncogene 2014; 33: 1601-1608.
33. Di Agostino S, Strano S, Emiliozzi V, Zerbini V, Mottolese M, Sacchi A et al. Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 2006; 10: 191-202.
34. Cooks T, Pateras IS, Tarcic O, Solomon H, Schetter AJ, Wilder S et al. Mutant p53 prolongs NF-kappaB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell 2013; 23: 634-646.
35. Byrne FL, Yang L, Phillips PA, Hansford LM, Fletcher JI, Ormandy CJ et al. RNAi-mediated stathmin suppression reduces lung metastasis in an orthotopic neuroblastoma mouse model. Oncogene 2014; 33: 882-890.
36. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 2010; 123: 725-731.
37. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 2005; 102: 13550-13555.
38. Messai Y, Noman MZ, Hasmim M, Janji B, Tittarelli A, Boutet M et al. ITPR1 protects renal cancer cells against natural killer cells by inducing autophagy. Cancer Res 2014; 74: 6820-6832.
39. Chen YW, Paliwal S, Draheim K, Grossman SR, Lewis BC. p19Arf inhibits the invasion of hepatocellular carcinoma cells by binding to C-terminal binding protein. Cancer Res 2008; 68: 476-482.
40. Goto Y, Nishikawa R, Kojima S, Chiyomaru T, Enokida H, Inoguchi S et al. Tumoursuppressive microRNA-224 inhibits cancer cell migration and invasion via targeting oncogenic TPD52 in prostate cancer. FEBS Lett 2014; 588: 1973-1982.
41. Shan J, Dsouza SP, Bakhru S, Al-Azwani EK, Ascierto ML, Sastry KS et al. TNRC9 downregulates BRCA1 expression and promotes breast cancer aggressiveness. Cancer Res 2013; 73: 2840-2849.
42. Li X, Yang Q, Yu H, Wu L, Zhao Y, Zhang C et al. LIF promotes tumorigenesis and metastasis of breast cancer through the AKT-mTOR pathway. Oncotarget 2014; 5: 788-801.
43. Liu J, Zhang C, Lin M, Zhu W, Liang Y, Hong X et al. Glutaminase 2 negatively regulates the PI3K/AKT signaling and shows tumor suppression activity in human hepatocellular carcinoma. Oncotarget 2014; 5: 2635-2647.
44. Yu H, Yue X, Zhao Y, Li X, Wu L, Zhang C et al. LIF negatively regulates tumoursuppressor p53 through Stat3/ID1/MDM2 in colorectal cancers. Nat Commun 2014; 5: 5218.
45. Hu W, Chan CS, Wu R, Zhang C, Sun Y, Song JS et al. Negative regulation of tumor suppressor p53 by microRNA miR-504. Mol Cell 2010; 38: 689-699.